📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly cited specific numbers: $60M total revenue, 102 commercial patients (up from 85), 24% QoQ growth, ~49% overall and ~61% earlier-line response rates, $562K price, and reiterated $250M-$300M FY2025 guidance. The language was forward-looking but anchored in concrete data.

Q3 2025

Confident Specific

Management repeatedly used precise figures (13% revenue growth, 43% gross margin, 26% lung cancer ORR) and reaffirmed guidance with conviction, but also displayed caution by keeping wide revenue range unchanged and dodging patient infusion counts.

Q4 2025

Confident Specific

Management used phrases like 'substantial revenue growth', 'best-ever 50% margin', 'remarkable growth in 2026', and gave concrete numbers (30% QoQ revenue growth, $264M full-year revenue) without hedging. They also provided specific pipeline milestones (Fast Track, sarcoma 50% ORR) and reiterated a $1B+ peak sales view.

Q1 2026 latest

Confident Specific

Management provided specific revenue guidance for Q2 and full year, highlighted record demand in March, and emphasized cost discipline with R&D declining for third consecutive quarter.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis appears stronger after this call. Management delivered specific revenue guidance for Q2 and full year 2026, which provides clearer near-term visibility. The 45% year-over-year revenue growth, record March demand, and resumed in-house manufacturing indicate commercial execution is improving. Pipeline progress in endometrial cancer (40% ORR) adds optionality, while cost discipline extended cash runway into 2028. However, gross margin recovery and regulatory updates (lung data, TILVANCE-301 enrollment) remain key watch items for next quarter. The increased sales force and expanding ATC network (especially community sites) should support continued demand growth.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Iovance Q1'26: AMTAGVI rev $60M, guides full year $350-370M, cash to 2028.

Revenue & Profitability

First quarter 2026 total revenue was $71 million, a 45% year-over-year increase. AMTAGVI revenue was $60 million (up 38% year-over-year), and Proleukin revenue was $11 million (nearly doubled year-over-year). Gross margin was about 41%, impacted by one-time non-recurring facility upgrade costs. The company had approximately $319 million in cash and equivalents as of March 31, 2026, and expects to fund operations into 2028. Research and development expenses declined for the third consecutive quarter, down 18% year-over-year.

Outlook

Management noted strong demand trends for AMTAGVI, with March 2026 being the largest reported revenue month to date. They expect continued growth driven by ATC network expansion, earlier patient referrals, and increasing physician awareness. The company sees significant unmet need in second-line metastatic serous endometrial cancer (response rates below 15%) and in non-small cell lung cancer (a market about seven times larger than the advanced melanoma opportunity). Ex-U.S., regulatory decisions are anticipated in Australia (first half 2026) and Switzerland (2027).

Growth Drivers

Key growth levers include expanding the ATC network to over 110 by year-end (with a growing mix of community ATCs), driving earlier referrals with real-world evidence and five-year durability data, and increasing the field sales force. Pipeline expansion into new indications such as metastatic serous endometrial cancer (40% confirmed ORR), non-small cell lung cancer (Fast Track designation), and soft tissue sarcomas (IOV-SAR-201 trial starting Q3 2026) also supports long-term growth. Next-generation programs (IOV-5001, IOV-3001, IOV-4001) target larger patient populations.

Balance Sheet & CapEx

Not discussed in this earnings call beyond the completed maintenance upgrades at the internal manufacturing facility (ICTC), which were described as one-time non-recurring costs that should not recur. No specific CapEx guidance or future infrastructure investments were mentioned.

Margins

First quarter gross margin was about 41%, absorbing one-time non-recurring costs related to facility upgrades. Management expects margins to trend higher for the rest of 2026 as in-house manufacturing scales and operational efficiencies improve. Cost of sales is expected to benefit from exclusive in-house production, economies of scale, and targeted operational excellence projects in the plant. The company is on a clear path to profitability.

Key Risks

No specific risks were flagged by management in the prepared remarks or Q&A beyond the standard forward-looking statement disclaimer about risks and uncertainties in SEC filings. Analysts did not raise risk-related questions.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Record Q2 revenue and margin were driven by robust Amtagvi demand, expanding ATC network, and operational efficiencies. Pipeline advanced with key regulatory milestones and international approvals, while strong cash reserves support ongoing growth and R&D.

Q1 2026 Q1 2026 2026-05-07

Q1 2026 revenue grew 45% year-over-year, driven by strong AMTAGVI demand and operational efficiencies. Guidance for Q2 and full-year 2026 remains robust, with margins expected to improve and a broadening pipeline targeting multiple solid tumor indications.

Q4 2025 Q4 2025 2026-02-24

Q4 and full-year 2025 saw 61% revenue growth, record gross margins, and strong AMTAGVI adoption. Pipeline advances include FDA Fast Track for lifileucel in lung cancer and positive sarcoma data, with global expansion and further revenue growth expected in 2026.

Q3 2025 Q3 2025 2025-11-06

Q3 revenue rose 13% sequentially to $68M, with gross margin improving to 43% due to cost reductions. Amtagvi and Proleukin sales drove growth, and strong clinical data in NSCLC support future expansion. Revenue guidance of $250–300M for 2025 is reaffirmed.

Q2 2025 Q2 2025 2025-08-07

Q2 2025 revenue grew 22% sequentially to $60M, driven by record Amtagvi infusions and strong demand. Strategic restructuring is set to deliver $100M+ in annual savings and margin improvement, with guidance reaffirmed at $250–$300M for the year.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.